| HbA1c level | Antidiabetic medication | |||||||
---|---|---|---|---|---|---|---|---|---|
 | ≤ 5.0 | 5.1–5.4 | 5.5–6.4 | ≤ 6.5 | |||||
No. of subjects at risk | 955 | 923 | Â | 736 | Â | 104 | Â | 133 | Â |
Total cardiovascular disease (n) | 19 | 31 | Â | 39 | Â | 12 | Â | 18 | Â |
Age- and sex-adjusted HR (95% CI) | 1.00 | 1.56 | (0.88–2.78) | 2.19 | (1.26–3.81)b | 4.94 | (2.39–10.2)b | 4.53 | (2.36–8.69)b |
Multivariable-adjusted HR (95% CI) | 1.00 | 1.60 | (0.90–2.85) | 2.26 | (1.29–3.95)b | 4.43 | (2.09–9.37)b | 5.15 | (2.65–10.0)b |
Coronary heart disease (n) | 8 | 10 | Â | 17 | Â | 5 | Â | 8 | Â |
Age- and sex-adjusted HR (95% CI) | 1.00 | 1.24 | (0.49–3.16) | 2.28 | (0.98–5.31) | 4.63 | (1.51–14.2)b | 4.30 | (1.61–11.5)b |
Multivariable-adjusted HR (95% CI) | 1.00 | 1.15 | (0.45–2.93) | 2.11 | (0.90–4.95) | 3.55 | (1.11–11.3)a | 4.39 | (1.60–12.0)b |
Ischaemic stroke (n) | 5 | 13 | Â | 15 | Â | 6 | Â | 7 | Â |
Age- and sex-adjusted HR (95% CI) | 1.00 | 2.42 | (0.86–6.82) | 3.19 | (1.15–8.83)a | 9.47 | (2.88–31.1)b | 6.99 | (2.18–22.4)b |
Multivariable-adjusted HR (95% CI) | 1.00 | 2.57 | (0.91–7.29) | 3.57 | (1.27–10.0)a | 9.65 | (2.81–33.1)b | 8.33 | (2.54–27.3)b |
Haemorrhagic stroke (n) | 6 | 8 | Â | 10 | Â | 2 | Â | 3 | Â |
Age- and sex-adjusted HR (95% CI) | 1.00 | 1.26 | (0.44–3.66) | 1.77 | (0.64–4.91) | 2.58 | (0.52–12.8) | 2.38 | (0.58–9.66) |
Multivariable-adjusted HR (95% CI) | 1.00 | 1.42 | (0.48–4.14) | 1.87 | (0.66–5.25) | 2.41 | (0.46–12.5) | 2.70 | (0.65–11.3) |